Techno Medical Public Co. Ltd.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR carries a market capitalization of 286.44M, placing it among publicly traded companies globally. Its enterprise value stands at 631.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR has 308.00M shares outstanding.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR trades at a trailing price-to-earnings ratio of 9.33. The price-to-sales ratio is 0.40, and the price-to-book ratio stands at 0.66.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR trades at an EV/EBITDA multiple of 7.34 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Techno Medical Public Company Ltd NVDR trades at an EV/FCF ratio of 1.46, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 631.46M versus a market cap of 286.44M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR maintains a current ratio of 1.48, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 77.38, indicating elevated leverage, while an interest coverage ratio of 7.53 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Techno Medical Public Company Ltd NVDR posted a return on equity (ROE) of 7.39, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.98 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.11, useful for judging operating efficiency across full business cycles. The company generates approximately 7.32M in revenue per employee across its workforce of 98.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.32 indicates how many times Techno Medical Public Company Ltd NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Techno Medical Public Company Ltd NVDR recorded 13.46M in income tax expense. That works out to an effective tax rate of 34.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 39.05M, leaving 30.69M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Techno Medical Public Company Ltd NVDR's stock has gained approximately 19.23% over the past 52 weeks. The 50-day moving average sits at 1.25, while the 200-day moving average is 0.97.

Over the twelve months ended June 30, 2026, Techno Medical Public Company Ltd NVDR generated 716.96M in revenue and converted that into 30.69M in net income, yielding earnings per share of 0.08. EBITDA reached 85.99M, while operating income came in at 50.77M.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR holds 46.26M in cash and equivalents against 358.79M in total debt, resulting in a net debt position of 298.76M. Total book value stands at 431.17M, with working capital of 172.32M providing operational flexibility.

Techno Medical Public Company Ltd NVDR produced 433.84M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.07M in capital expenditures, free cash flow totaled 425.77M - equivalent to 1.38 per share.

Over the twelve months ended June 30, 2026, Techno Medical Public Company Ltd NVDR posted a gross margin of 36.87, reflecting its pricing power and cost economics. The operating margin of 7.08 and net profit margin of 4.28 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Techno Medical Public Company Ltd NVDR paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 148.64, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 167.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Techno Medical Public Company Ltd NVDR shareholders.

Techno Medical Public Company Ltd NVDR's most recent stock split took place on April 27, 2017 with a 10:11 split ratio.

As of June 30, 2026, Techno Medical Public Company Ltd NVDR has an Altman Z-Score of 1.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.